After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results

© Reuters. After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results

After-Hours Stock Movers:

Global Blood Therapeutics (NASDAQ:GBT) 30% HIGHER; said to draw takeover interest - Bloomberg

Yellow Corporation (YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.

Lucid Group (LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.

MercadoLibre (NASDAQ:MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.

Skillz (SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.

Medifast (NYSE:MED) (MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.

Fortinet (NASDAQ:FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.

PacBio (PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.

Clorox (NYSE:CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.

Lumen Technologies (LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook

Albemarle (NYSE:ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.

Sunrun (NASDAQ:RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.

Qorvo (NASDAQ:QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.